Journal ArticleDOI
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar,Bruno Paiva,Kenneth C. Anderson,Brian G.M. Durie,Ola Landgren,Philippe Moreau,Nikhil C. Munshi,Sagar Lonial,Joan Bladé,Maria-Victoria Mateos,Meletios A. Dimopoulos,Efstathios Kastritis,Mario Boccadoro,Mario Boccadoro,Robert Z. Orlowski,Hartmut Goldschmidt,Andrew Spencer,Jian Hou,Wee Joo Chng,Saad Z. Usmani,Elena Zamagni,Kazuyuki Shimizu,Sundar Jagannath,Hans Erik Johnsen,Evangelos Terpos,Anthony Reiman,Robert A. Kyle,Pieter Sonneveld,Paul G. Richardson,Philip L. McCarthy,Heinz Ludwig,Wenming Chen,Michele Cavo,Jean Luc Harousseau,Suzanne Lentzsch,Jens Hillengass,Antonio Palumbo,Alberto Orfao,S. Vincent Rajkumar,Jesús F. San Miguel,Hervé Avet-Loiseau +40 more
TLDR
Several aspects of disease response assessment are clarified, along with endpoints for clinical trials, and future directions for disease response assessments are highlighted, to allow uniform reporting within and outside clinical trials.Abstract:
Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth of response. Response criteria in multiple myeloma were developed to use serum and urine assessment of monoclonal proteins and bone marrow assessment (which is relatively insensitive). Given the high rates of complete response seen in patients with multiple myeloma with new treatment approaches, new response categories need to be defined that can identify responses that are deeper than those conventionally defined as complete response. Recent attempts have focused on the identification of residual tumour cells in the bone marrow using flow cytometry or gene sequencing. Furthermore, sensitive imaging techniques can be used to detect the presence of residual disease outside of the bone marrow. Combining these new methods, the International Myeloma Working Group has defined new response categories of minimal residual disease negativity, with or without imaging-based absence of extramedullary disease, to allow uniform reporting within and outside clinical trials. In this Review, we clarify several aspects of disease response assessment, along with endpoints for clinical trials, and highlight future directions for disease response assessments.read more
Citations
More filters
Journal ArticleDOI
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
TL;DR: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal,Valérie Lauwers-Cances,Cyrille Hulin,Xavier Leleu,Denis Caillot,Martine Escoffre,Bertrand Arnulf,Margaret Macro,Karim Belhadj,Laurent Garderet,Murielle Roussel,Catherine Payen,Claire Mathiot,Jean Paul Fermand,Nathalie Meuleman,Sandrine Rollet,Michelle E. Maglio,Andrea A. Zeytoonjian,Edie Weller,Nikhil C. Munshi,Kenneth C. Anderson,Paul G. Richardson,Thierry Facon,Hervé Avet-Loiseau,Jean-Luc Harousseau,Philippe Moreau +25 more
TL;DR: Among adults with multiple myeloma, RVD therapy plus transplantation was associated with significantly longer progression‐free survival than RVD Therapy alone, but overall survival did not differ significantly between the two approaches.
Journal ArticleDOI
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi,Larry D Anderson,Nina Shah,Deepu Madduri,Jesus G. Berdeja,Sagar Lonial,Noopur Raje,Yi Lin,David S. Siegel,A. Oriol,Philippe Moreau,Ibrahim Yakoub-Agha,Michel Delforge,Michele Cavo,Hermann Einsele,Hartmut Goldschmidt,Hartmut Goldschmidt,Katja Weisel,Katja Weisel,Alessandro Rambaldi,Alessandro Rambaldi,Donna Reece,Fabio Petrocca,Monica Massaro,Jamie N Connarn,Shari Kaiser,Payal Patel,Liping Huang,Timothy B. Campbell,Kristen Hege,Jesús F. San-Miguel +30 more
TL;DR: In this article, a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expecable clinical outcomes with the use of idecabtagene vicleucel (ide-cel), also called bb2121.
Journal ArticleDOI
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Maria-Victoria Mateos,Meletios A. Dimopoulos,Michele Cavo,Kenshi Suzuki,Andrzej Jakubowiak,Stefan Knop,Chantal Doyen,Paulo Sérgio Lucio,Zsolt Nagy,Polina Kaplan,Ludek Pour,Mark Cook,Sebastian Grosicki,Andre Crepaldi,Anna Marina Liberati,Philip Campbell,Tatiana Shelekhova,Sung-Soo Yoon,Genadi Iosava,Tomoaki Fujisaki,Mamta Garg,Christopher Chiu,Jianping Wang,Robin Carson,Wendy Crist,William Deraedt,Huong Nguyen,Ming Qi,Jesús F. San-Miguel +28 more
TL;DR: Among patients with newly diagnosed multiple myeloma who were ineligible for stem‐cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without darumumab.
Journal ArticleDOI
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Philippe Moreau,J F San Miguel,Pieter Sonneveld,Maria-Victoria Mateos,Elena Zamagni,Hervé Avet-Loiseau,Roman Hájek,Meletios A. Dimopoulos,Heinz Ludwig,H. Einsele,Sonja Zweegman,Thierry Facon,Michele Cavo,Evangelos Terpos,H. Goldschmidt,M. Attal,Christian Buske +16 more
TL;DR: These Clinical Practice Guidelines are endorsed by the Japanese Society of Medical Oncology (JSMO) incidence and epidemiology Multiple myeloma accounts for 1% ofall cancers and ∼10% of all haematological malignancies.
References
More filters
Journal ArticleDOI
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar,Meletios A. Dimopoulos,Antonio Palumbo,Joan Bladé,Giampaolo Merlini,Maria-Victoria Mateos,Shaji Kumar,Jens Hillengass,Efstathios Kastritis,Paul G. Richardson,Ola Landgren,Bruno Paiva,Angela Dispenzieri,Brendan M. Weiss,Xavier Leleu,Sonja Zweegman,Sagar Lonial,Laura Rosiñol,Elena Zamagni,Sundar Jagannath,O. Sezer,Sigurdur Y. Kristinsson,Jo Caers,Saad Z. Usmani,Juan José Lahuerta,Hans Erik Johnsen,Meral Beksac,Michele Cavo,Hartmut Goldschmidt,Evangelos Terpos,Robert A. Kyle,Kenneth C. Anderson,Brian G.M. Durie,Jesús F. San Miguel +33 more
TL;DR: The disease definition of multiple myeloma is updated to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions), and specific metrics that new biomarkers should meet for inclusion in the disease definition are provided.
Journal ArticleDOI
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Michel Attal,Jean-Luc Harousseau,Anne-Marie Stoppa,Jean-Jacques Sotto,Jean-Gabriel Fuzibet,Jean-François Rossi,Philippe Casassus,Hervé Maisonneuve,Thierry Facon,Norbert Ifrah,Catherine Payen,Régis Bataille +11 more
TL;DR: The response rate among the patients who received high-dose therapy was 81 percent, whereas it was 57 percent in the group treated with conventional chemotherapy (P<0.001).
Journal ArticleDOI
International uniform response criteria for multiple myeloma
Brian G.M. Durie,J L Harousseau,Jesús F. San Miguel,J. Bladé,Bart Barlogie,Kenneth C. Anderson,Morie A. Gertz,Meletios A. Dimopoulos,Johan Westin,Pieter Sonneveld,Heinz Ludwig,G. Gahrton,Meral Beksac,John Crowley,Andrew Belch,M. Boccadaro,Ingemar Turesson,Douglas E. Joshua,David H. Vesole,Robert A. Kyle,Raymond Alexanian,Guido Tricot,M. Attal,Giampaolo Merlini,R. L. Powles,Paul G. Richardson,K. Shimizu,Patrizia Tosi,Gareth J. Morgan,S V Rajkumar +29 more
TL;DR: The European Group for Blood and Bone Marrow Transplant/International Bone Marrows Transplant Registry criteria have been expanded, clarified and updated to provide a new comprehensive evaluation system to adequately assess clinical outcomes in myeloma.
Journal ArticleDOI
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
J. Anthony Child,Gareth J. Morgan,Faith E. Davies,Roger G. Owen,Sue E. Bell,Kim Hawkins,Julia Brown,Mark T. Drayson,Peter Selby +8 more
TL;DR: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age and trend toward a greater survival benefit in the group of patients with a poor prognosis.
Journal ArticleDOI
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington,N. George Mikhaeel,Lale Kostakoglu,Michel Meignan,Martin Hutchings,Stefan P. Müeller,Lawrence H. Schwartz,Emanuele Zucca,Richard I. Fisher,Judith Trotman,Otto S. Hoekstra,Rodney J. Hicks,Michael O'Doherty,Roland Hustinx,Alberto Biggi,Bruce D. Cheson +15 more
TL;DR: This article comprises the consensus reached to update guidance on the use of PET-CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practice and late-phase trials.
Related Papers (5)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar,Meletios A. Dimopoulos,Antonio Palumbo,Joan Bladé,Giampaolo Merlini,Maria-Victoria Mateos,Shaji Kumar,Jens Hillengass,Efstathios Kastritis,Paul G. Richardson,Ola Landgren,Bruno Paiva,Angela Dispenzieri,Brendan M. Weiss,Xavier Leleu,Sonja Zweegman,Sagar Lonial,Laura Rosiñol,Elena Zamagni,Sundar Jagannath,O. Sezer,Sigurdur Y. Kristinsson,Jo Caers,Saad Z. Usmani,Juan José Lahuerta,Hans Erik Johnsen,Meral Beksac,Michele Cavo,Hartmut Goldschmidt,Evangelos Terpos,Robert A. Kyle,Kenneth C. Anderson,Brian G.M. Durie,Jesús F. San Miguel +33 more
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo,Hervé Avet-Loiseau,Stefania Oliva,Henk M. Lokhorst,Hartmut Goldschmidt,Laura Rosiñol,Paul G. Richardson,S. Caltagirone,Juan J. Lahuerta,Thierry Facon,Sara Bringhen,Michel Attal,Roberto Passera,Andrew Spencer,Massimo Offidani,Shantanu Kumar,Pellegrino Musto,Sagar Lonial,Maria Teresa Petrucci,Robert Z. Orlowski,Elena Zamagni,Gareth J. Morgan,Maletios A. Dimopoulos,Brian G.M. Durie,Kenneth C. Anderson,Pieter Sonneveld,Jesús F. San Miguel,Michele Cavo,S. Vincent Rajkumar,Philippe Moreau +29 more
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
International uniform response criteria for multiple myeloma
Brian G.M. Durie,J L Harousseau,Jesús F. San Miguel,J. Bladé,Bart Barlogie,Kenneth C. Anderson,Morie A. Gertz,Meletios A. Dimopoulos,Johan Westin,Pieter Sonneveld,Heinz Ludwig,G. Gahrton,Meral Beksac,John Crowley,Andrew Belch,M. Boccadaro,Ingemar Turesson,Douglas E. Joshua,David H. Vesole,Robert A. Kyle,Raymond Alexanian,Guido Tricot,M. Attal,Giampaolo Merlini,R. L. Powles,Paul G. Richardson,K. Shimizu,Patrizia Tosi,Gareth J. Morgan,S V Rajkumar +29 more